Antidepressant, Anxiolytic and Neuroprotective Activities of Two Zinc Compounds in Diabetic Rats

Christiane Leite Cavalcanti1,2, Maria Conceição Rodrigues Gonçalves1, Adriano Francisco Alves3, Emmanuel Veríssimo de Araújo2, Jader Luciano P. Carvalho2, Priscilla Paulo Lins2, Raquel Coutinho Alves2, Nais Lira Soares2, Liana Clebia Morais Pordeus1 and Jailane Souza Aquino1,2*

1 Programa de Pós Graduação em Ciências da Nutrição, Universidade Federal da Paraíba, João Pessoa, Brazil, 2 Laboratório de Nutrição Experimental, Universidade Federal da Paraíba, João Pessoa, Brazil, 3 Laboratório de Patologia, Universidade Federal da Paraíba, João Pessoa, Brazil

Behavioral disorders affect most diabetic patients and Zinc (Zn) has been used among adjuvant therapies for involvement in the etiology of depression and anxiety, however, the results are still controversial. The objective of this study was to compare the antidepressant, anxiolytic and neuroprotective activity of the supplementation of two Zn compounds in an animal model of Diabetes Mellitus type 1 (DM1). Thirty-eight (38) adult rats were randomized into four groups: Control (C; n = 8); Diabetic (D; n = 10); Diabetic Zn Sulfate Supplement (DSZ; n = 10) and Diabetic Zn Gluconate Supplement (DGZ; n = 10). The DSZ group received Zn sulfate supplementation and the DGZ group received Zn gluconate supplementation at a dose of 15 mg/kg for 4 weeks. Data (mean ±SEM) were analyzed by the Mann–Whitney test with a significance level of p < 0.05. The results indicate that Zn gluconate supplementation in diabetic animals presented an antidepressant effect demonstrated through the results obtained in the Forced Swim Test, and neuroprotective effect by attenuating alterations in the cerebral cortex; while Zn sulfate supplementation in diabetic animals showed an anxiolytic effect demonstrated by the results obtained in the open field test and the elevated plus maze test. Considering the set of results, supplementation with both zinc compounds showed neurobehavioral benefits in diabetic animals with different effects depending on the type of anion associated with Zn.

Keywords: anxiety, depression, supplementation, zinc, diabetic rats

INTRODUCTION

Diabetes mellitus type 1 (T1DM) is a chronic disease characterized by insulin deficiency due to pancreatic β-cell loss and leads to hyperglycemia (American Diabetes Association, 2017). Diabetes Mellitus (DM) is a public health problem due to the large number of people affected and the consequences of the disease, that contribute to decreasing the quality of life of patients (American Diabetes Association, 2017). Studies have shown that DM is related to an increased prevalence of psychiatric disorders, among which depression and anxiety (Rotella and Mannucci, 2013; Petrak et al., 2015) are noteworthy.

Depression is a common, chronic, and disabling psychiatric disorder, strongly related to an anonymous state (Strandberg et al., 2014) resulting in social and economic burden, as well as
enormous personal suffering and increased risk of mortality (Lépine and Briley, 2011). This disorder has been postulated to play a causal role in DM, and an increased risk has been reported in 60% of depressive individuals in developing this disease (Balhara, 2011). Similarly, the prevalence of anxiety disorders among diabetic patients is considerably higher compared to the general population (Huang et al., 2012).

In this context, it is imperative to seek adjutants in treating diabetes and in preventing these disorders. Studies have related diabetes to zinc deficiency (Fernando and Zhou, 2015; Ranasinghe et al., 2015), even though this essential trace element is often present in the diets of diabetics in dietary sources such as eggs, cheese, meat, vegetables, whole grains, nuts and cereals, in addition to others such as several chemical form factors, the presence of absorption inhibitors or promoters, age and nutritional status of the individual may compromise their bioavailability in the body (Gibson, 2012). Zinc (Zn) plays substantial roles in inflammation suppression, oxidative stress reduction and in the correct functioning of lipid and glucose metabolism (Olechnowicz et al., 2018), especially in the brain, with higher concentrations being found in the hippocampus and amygdala regions (Grönl i J. et al., 2013). Moreover, 300 enzymes are dependent on this trace element, many of them expressed in the central nervous system (Hagmeyer et al., 2015).

Zn deprivation affects brain homeostasis, leading to behavioral, cognitive and mental changes (Partyka et al., 2011; Szweczyk et al., 2011). In this sense, experimental and clinical observations have suggested that Zn is involved in the pathophysiology of depression and anxiety (Szweczyk et al., 2008; Mlyniec et al., 2014).

In fact, some studies suggest Zn as a protective agent against brain damage (Szweczyk, 2013), although it's excess may produce cytotoxic effects (Sensi and Jeng, 2004; Plum et al., 2010). However, in clinical studies, the association between the prevalence of psychiatric disorders and zinc deficiency is controversial (Nguyen et al., 2009; Irmisch et al., 2010; Grönl i O. et al., 2013).

Some studies with animals have shown that Zn deficiency increases symptoms which are similar to those of depression (Tassabehji et al., 2008; Mlyniec et al., 2012), while others have shown that Zn deficiency-like symptoms similar to depression appear to be reversed by antidepressant treatment (Whittle et al., 2008; Mlyniec and Nowak, 2012; Mlyniec et al., 2012). Other non-clinical studies have demonstrated a more expressive type of depressant behavior in animals with induced diabetes (Wayhs et al., 2013; De Morais et al., 2014).

Different Zn compounds such as oxides, hydroaspartate, chloride were intraperitoneally administered at varying doses (Joshi et al., 2012; Torabi et al., 2013; Satafa et al., 2016) to test antidepressant properties in several behavioral tests, suggesting that Zn may potentiate the action of antidepressants, in addition to reducing their side effects so that their supplementation has a therapeutic effect (Siwek et al., 2018; Ranjbar et al., 2013). Zn sulfate and gluconate are the most common compounds administered orally (Capdor et al., 2013; Roohani et al., 2013), with the choice of this route being important in T1DM since patients already use injectable insulin. However, their actions so far have been poorly elucidated in behavioral tests in diabetic animals.

In this context, experimental studies involving Zn supplementation in diabetic rats substantially contribute to better understanding behavioral disorders, specifically depression and anxiety, as well as being essential for the safe prescription of Zn supplementation as an adjuvant treatment alternative. Thus, the present study aimed to compare the antidepressant, anxiolytic and neuroprotective activity of supplementing two Zn compounds in an animal model of Diabetes Mellitus Type 1 (T1DM).

**MATERIALS AND METHODS**

**Experimental Protocol**

The experiments and protocols performed with the animals are in accordance with the principles recommended by Institute of Laboratory Animal Resources (2011). The protocols were approved by the Ethics Committee on Animal Use (CEUA) of the Federal University of Paraíba (UFPB), under no. 045/2015.

A total of 38 male adult Wistar (*Rattus norvegicus*, variety *albinus*) rats weighing 250 ± 30 g from Thomas George (UFPB) were used. The animals were housed in individual metabolic cages and maintained under standard lighting conditions (light/dark cycle, 12/12 h) and temperature (22 ± 2°C). Commercial ration (Presence, Paulínea, São Paulo) and filtered water were offered *ad libitum*. After 1 week of acclimatization, the animals were randomized into four groups: Control (C; *n* = 8); Diabetic (D; *n* = 10); Diabetic Zn sulfate supplemented (DSZ; *n* = 10) and Diabetic Zn gluconate supplemented (DGZ; *n* = 10) (*Supplementary Figure S1*). Data from healthy groups supplemented with zinc sulfate (SZ, *n* = 8) and zinc gluconate (GZ, *n* = 8) were presented as *Supplementary Figures S2, S3*.

**Induction of Diabetes Mellitus Type 1 (T1DM)**

The procedure for chemical induction of diabetes in the animals of the D, DSZ and DGZ groups was performed after a 12-h fast. A solution of streptozotocin (STZ, Sigma-Aldrich, St. Louis, MO, United States) dissolved in citrate buffer (0.1 M, pH = 4.5) was intraperitoneally administered in a single dose of 50 mg/kg body weight (Santos et al., 2014). Group C intraperitoneally received equivalent doses of citrate buffer (0.1 M, pH = 4.5), without the addition of STZ. Three days after induction, animals that received glycemia greater than 250 mg/dL were considered diabetic and included in the experimental groups (Santos et al., 2014).

**Zinc Supplementation**

The animals in the DSZ group received Zn sulfate supplementation and the animals in the DGZ group received Zn gluconate supplementation, both compounds oro-gastrically administered at a dose of 15 mg/kg body weight/day once daily for 4 weeks (Sapota et al., 2014). The dose choice used complied with the recommended maximum limit for rodents (National Academy of Sciences, 2001) and humans.
Behavioral Parameters
The animals of all groups were submitted to behavioral tests at the end of the 4 weeks of supplementation, and each test was performed on subsequent days. Ideal conditions were maintained for these tests: attenuation of noise levels, low illumination intensity and controlled temperature (±25°C). The animals were taken to the test room for acclimatization and adaptation half an hour before the experiments were performed.

Evaluation of Anxiolytic Activity
Anxiolytic activity was evaluated by the Elevated Plus Maze (EPM), in which behavioral conflict is based on the animal's need to explore the environment and the potential danger it poses (Pellow et al., 1985).

The apparatus (Insight brand, Madeira, EP 151, Ribeirão Preto, São Paulo, Brazil) consists of a platform with two open arms (50 cm × 10 cm) perpendicular to two closed arms (50 cm × 10 cm × 50 cm), forming a cross and raised 50 cm from the ground. There is an acrylic border of 1 cm in height surrounding the open arms in order to avoid falls by the animals. Each animal was positioned in the center of the apparatus facing one of the closed arms and allowed to operate the apparatus for 5 min. Animal preference for open or closed arms was evaluated. An observer made the annotations regarding the percentage of entries in the open arms and closed arms, length of stay in each arms and total number of arm entries (open arm entries + close arm entries). The apparatus was cleaned with 10% ethyl alcohol and paper towels before and after the exposure of each animal, allowing it to dry naturally.

Motor Activity Assessment
The exploratory activity was evaluated by the Open Field (OF) test (Candland and Campbell, 1962), used for evaluating stimulant compounds or CNS depressants. The apparatus (Insight brand, EP 154, Ribeirão Preto, São Paulo, Brazil) consists of a circular, transparent acrylic box measuring 50 cm in height and 60 cm in diameter. The white acrylic floor (100 × 80 cm) is divided into concentric circles (15, 34, and 55 cm radius) and black radial lines forming 12 quadrants of similar areas. The animals were individually placed in the center of the device and the following behaviors were then observed during 5 min: a manual counter was used for recording ambulation (number of entries by the animal with four legs into any of the squares), rearing (number of times the animal is raised on its hind legs, perpendicular to the ground), grooming (number of times the animal self-cleans), immobility time (complete immobility of the animal) and number of fecal cakes. There was a specific observer for each evaluated behavior, totaling four properly trained observers. The apparatus was cleaned with 10% ethyl alcohol and paper towels before and after the exposure of each animal, allowing it to dry naturally.

Evaluation of Antidepressant Activity
Antidepressant activity was evaluated by the Forced Swim Test (FST) through observation of animal behavior in the face of an unconditioned stress situation (Porsolt, 1979).

A cylinder (30 cm in diameter and 50 cm in height) was used with water at a depth of 30 cm and temperature (25 ± 2°C). The animals were taken to the antechamber, where they remained for 30 min. After that time, the animals were individually placed in the cylinder with water and submitted to the test for 5 min in a single session, with their active (swimming and climbing) and passive behavior (immobility) evaluated (Slattery and Cryan, 2012). The evaluations were performed by two observers and filmed, then later transferred to a computer and analyzed in detail. At the end of the test the animals were dried with cloth towels. The water was exchanged before and after exposure of each animal, and the apparatus was cleaned with 10% ethyl alcohol, allowing it to dry naturally.

Euthanasia
After 8 h fasting, the animals were intraperitoneally anesthetized with ketamine (25 mg/kg) associated with xylazine (25 mg/kg). The absence of reflexes was confirmed after anesthesia and the brains were collected for histological analysis.

Histological Analysis of the Brain
The brains (right hemisphere) of each animal were sanitized with saline, fixed in 10% buffered formalin and stored in coded containers. The organs were processed according to the routine histopathological technique. Ten semi-serial cuts of 5 μm thick were obtained from the paraffin embedded material, following a cross-sectional plane to the analyzed organ of each animal. The obtained slides were stained using Hematoxylin and Eosin (H and E) technique, and the assembly was performed between lamina and laminula with synthetic resin (Entellan-Merck) for analysis in increasing lenses and photographed at 100x total magnification under an optical microscope (Motic BA 200, Kowloon, Hong Kong). The structural architectures of the organs and the presence, characteristic and intensity of possible inflammatory infiltrates were evaluated in these analyses.

Statistical Analysis
Data sets were tested for normality and homogeneity using tests of variance. Behavioral data (mean ± SEM) were analyzed by the Mann–Whitney test. The accepted level of significance was \( p < 0.05 \). The results were expressed as mean and standard error of the mean and were analyzed in Prism 6.0 software (GraphPad, San Diego, CA, United States).

RESULTS
Behavioral Parameters of Diabetic Rats Supplemented With Two Different Zinc Compounds
The study highlights the importance of zinc supplementation in the attenuated of common behavioral disorders, depression and
anxiety in diabetes. Zn gluconate supplementation in diabetic animals reduced the time of passive behavior characterized by the animal’s immobility (116.6 ± 10.29 versus 164.4 ± 8.63 s, p < 0.05) and increased swimming time (24.12 ± 4.91 versus 11.5 ± 3.62 s, p < 0.05), both compared to group D (Figure 1). The active swimming behavior was similar between groups D and DSZ (p > 0.05).

Regarding the anxious type behavior measured in the Elevated Labyrinth Plus test (Figure 2), the diabetic group supplemented with Zn sulfate (DSZ) had longer length of stay in the open arms (3.12 ± 0.39 versus 1.12 ± 0.39, p < 0.05), higher frequency of open arm entries (22.13 ± 2.99 versus 7.87 ± 2.96 s, p < 0.05) and greater total number of open plus closed arm entries compared to group D (5.50 ± 0.56 versus 4.00 ± 0.53, p < 0.05). Whereas the DGZ group presented shorter length of stay in the open arms and higher frequency of open arms entry than the group D (p < 0.05).

The motor activity was measured using the Open Field (Figure 3). The DSZ group presented better responses as evidenced by greater ambulation (29.25 ± 0.90 versus 18.50 ± 2.24, p < 0.05) and shorter immobility time (3.12 ± 0.35 versus 6.87 ± 0.63 s, p < 0.05) compared to group D. The DGZ group had a shorter immobility time (3.87 ± 0.42 versus 6.87 ± 0.63 s, p < 0.05) compared to group D. In relation to the other evaluated parameters (rearing, grooming and number of fecal cakes) there were no differences (p > 0.05), so that these data were not included in the graphs (Supplementary Table S1).

**DISCUSSION**

Diabetic animals had longer immobility time on the FST compared to diabetic and Zn Gluconate supplemented animals, thus reflecting their called “despair behavior” (Wayhs et al., 2010). The existence of DM is associated with anxiety disorders and increases the probability depression occurring (Golden et al., 2008; Huang et al., 2012). Our results suggest potential Zn Gluconate antidepressant activity evidenced by the shorter immobility time (p < 0.05) compared to the D and DSZ groups, considering that immobility time is used as an index of depressive behavior (Slattery and Cryan, 2012).

The swimming time parameter was used for evaluating locomotor activity and the results also showed a significant increase in the DGZ (p < 0.05) compared to the D group. The other active behavior parameter (climbing) did not present a statistically significant difference between groups (p > 0.05). In this sense, it is important to note that healthy animals supplemented with Zn did not obtain significant changes in behavior during the behavioral tests in our study, and therefore we can suggest that the beneficial effect of Zn supplementation only occurred in diabetic animals (Supplementary Figure S2).

A previous study (Szewczyk et al., 2011) found that immobility time on the FST was significantly higher in Zn-deficient mice, suggesting that a deficiency of this trace element causes an increase in behavior similar to depression. Hyperactivity of the glutamatergic system occurs in situations of Zn deficiency, thus generating depressive behavior, as demonstrated by Slattery and Cryan (2012). Animals using an antidepressant allied to an adequate or supplemented with Zn diet for 3 weeks showed reduced behavioral despair as measured by the FST (Tassabehji et al., 2008).

In recent decades, the Elevated Plus Maze (EPM) has established itself as the most classic animal model of exploratory behavior used in the laboratory. The animal explores both the
open and closed arms of the labyrinth, but typically it will more frequently enter and will remain longer in the closed arms. However, a higher intensity of anxiety behavior equates to a lower preference for open arms and thus a higher predilection for closed arms (Ahn et al., 2013).

Our results demonstrated an increase in the length of stay and in the number of open arms ($p < 0.05$) in diabetic animals supplemented with Zn sulfate compared to the animals in groups D and DGZ, suggesting that this compound had an anxiolytic effect as confirmed by the longer stay in the open arms, and that the ambulation ability in these animals was preserved, indicating the ability of Zn to reduce anxiety without causing sedation.

In using the EPM to predict the potential anxiolytic activity of Zn hydroaspartate in rats and mice (Partyka et al., 2011) found an increase in the percentage of open arms entries in both species without significantly altering the length of stay in these arms. Zn chloride at different doses of Zn (15 and 20 mg/kg) promoted anxiolytic effects in supplemented rats, evidenced by the increase in the residence time and the greater number of open arms entries in the EPM (Joshi et al., 2012). Zn oxide supplementation at different doses (5 mg/kg and 10 mg/kg) resulted in an anxiolytic effect in the EPM test in rats (Torabi et al., 2013). However, a study on rats supplemented with Zn oxide at a higher dose (25 mg/kg) did not find a significant difference in the anxiety indexes assessed by the EPM (Amara et al., 2013).

In our study we evaluated five parameters: ambulation, latency time, rearing, grooming and fecal cakes. We realized that the abilities to explore the surrounding environment and spontaneous ability were severely impaired in group D, representing the behavioral and emotional changes that could mimic the clinical symptoms of depression. The increase in anxiety in OF is related to a decrease in locomotion and an increase in the peripheral area; an increased permanence
FIGURE 3 | Evaluation of motor activity using the Open Field Test in diabetic rats treated with two different zinc compounds (15 mg/kg). (A) Entry frequency and (B) Length of stay in closed arms. C, Control Group (n = 8); D, Diabetic Group (n = 10); DSZ (n = 10): Diabetic Group Supplemented with Zn Sulfate and DGZ (n = 10): Diabetic Group Supplemented with Zn Gluconate (n = 10). Mann–Whitney test (p < 0.05).

FIGURE 4 | Histology of the cerebral cortex of diabetic rats treated with two different zinc compounds (H and E, × 100) C, control group (n = 8); D, diabetic group (n = 10), the arrow indicates ischemic neurons, the star indicates hemorrhage and the triangle indicates dilated vessels; DSZ, diabetic group supplemented with Zn Sulphate (n = 10), the arrow indicates ischemic neurons; DGZ: Diabetic Group Supplemented with Zn Gluconate (n = 10), the triangle indicates dilated vessels.

In the central portion of the field indicates anxiolytic effect, whereas a decrease in the permanence in the central part of the device can be interpreted as an anxiogenic effect (Ahn et al., 2013).

The OF arena is considered a stressful environment for fear. More anxious and emotional animals tend to wander less and stay away from the central part of the arena in such conditions (Takeda et al., 2007; Strandberg et al., 2014). Regarding the evaluated parameters, we noticed that Zn sulfate supplementation in the DSZ group animals improved their locomotor activity in the OF test, increased the number of crossed quadrants and decreased their immobility time (p < 0.05), indicating a lower anxiety level compared to the D and DGZ groups. These results allow for suggesting that the locomotor activity was preserved after administering Zn sulfate, so this Zn compound did not present sedative effect.

Were observed an increase in anxious behavior in Zn-deficient mice through less ambulation and less immobility during the OF test (Takeda et al., 2012). Rats fed a Zn-deficient diet for 2 weeks showed decreased ambulation and grooming, suggesting that anxiety-like behavior is increased in Zn deficiency (Xie et al., 2012). Behavioral changes may especially represent an effect of Zn deficiency and may be informative about the various pathways in which this trace element is an important functional factor in brain function (Hagmeyer et al., 2015).

In DM animal models, including the streptozotocin (STZ)-induced diabetic rodent model, abnormalities in the regulation of several neurotransmitters have been reported (Suzuki et al., 2012). Persisting hyperglycemia leads to impaired neurogenesis, decreased synaptic plasticity, undesired neuro-anatomical alterations, neurochemical deficits, and reduced neurotransmitter activity (Prabhakar et al., 2015). Zinc sulfate was not effective in improving the parameters evaluated in the FST and was effective in EPM and OF. While zinc gluconate was active in improving the parameters evaluated in FST and was not effective in EPM and OF. These data may indicate that the anion associated with Zn determines its antidepressant and anxiolytic activity. The antidepressant effect shown by Zn may be related to attenuation of the glutamatergic system by inhibition of N-methyl-D-aspartate (NMDA) receptor activity, as demonstrated in previous studies (Szewczyk et al., 2008, 2011; Mlyniec et al., 2012). Zn antidepressant and anxiolytic activities can also occur via modulating the serotonergic system through a complex mechanism not yet fully elucidated involving the participation of pre- and postsynaptic 5-HT1ARs (Satała et al., 2016). However, the mechanisms of how zinc-associated anions work in DM are not yet well understood.

Stress and anxiety have some parallels, as they appear to be genetically linked by sharing neurocircuits and common
brain areas, including the prefrontal cortex, hippocampus, and amygdale (Sartori et al., 2011). In this sense, it is interesting to analyze some brain structures in search of connections between the role of Zn and the brain. In our study, we investigated the cerebral cortex of the animals and verified that the diabetic animals presented alterations characterized by the presence of ischemic neurons, hemorrhaging and dilated vessels, characterizing the oxidative stress of DM1. It is known that DM is associated with learning deficits and oxidative imbalances, neurophysiological and structural changes in cerebral cortex (Ates et al., 2014; Kim et al., 2015).

In our study, supplementation with the two Zn compounds showed beneficial effects on the cerebral cortex of diabetic animals, since these organs had more preserved structures with a reduction in ischemic neurons and hemorrhaging, suggesting a potential neuroprotective effect; especially of the Zn Gluconate compound at doses within the recommended maximum limit for rodents (National Academy of Sciences, 2001). Were found beneficial effects in the brains of healthy rats supplemented with Zn chloride (5 mg/kg) demonstrated by decreasing the degeneration and preservation of neuronal cells (Brocardo et al., 2007).

We have a limitation related to the absence of the plasma Zn dosage for verifying the deficiency in the animals. However, in view of the obtained only in diabetic animals and those supplemented with the two Zn compounds, it can be suggested that the resulting benefits may be due to the Zn deficiency in these animals, which may confirm a possible relation between DM1, Zn deficiency and behavioral changes.

**CONCLUSION**

Considering the set of results, supplementation with both zinc compounds showed neurobehavioral benefits in diabetic animals with different effects depending on the type of anion associated with Zn: Zn gluconate had antidepressant and neuroprotective effect, while Zn sulfate had an anxiolytic effect, and further studies are needed to clarify how these mechanisms of action occur.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/Supplementary Material.

**REFERENCES**

Ahn, S. H., Jang, E. H., Choi, J. H., Lee, H. R., Bakes, J., Kong, Y. Y., et al. (2013). Basal anxiety during an open field test is correlated with individual differences in contextually conditioned fear in mice. *Anim. Cells Syst.* 17, 154–159. doi: 10.1080/19768354.2013.790840

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Ethics Committee on Animal Use (CEUA) of the Federal University of Paraíba (UFPB), under no. 045/2015.

**AUTHOR CONTRIBUTIONS**

CC, MG, LP, and JA designed the study and the experiments. CC, AA, EA, JC, RA, PL, and NS carried out the experiments. CC, LP, and JA analyzed the data. CC, AA, and JA implemented the reagents, materials, and analysis tools. CC and JA wrote the manuscript.

**FUNDING**

The Coordination for the Improvement of Higher Education Personnel (Capes) granted a scholarship to CC, financial code 001 and the Federal University of Paraíba for the physical and technical structure and for the payment of the publication fee (edict n. 02/2019/UFPB).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2019.01411/full#supplementary-material

**FIGURE S1** | Experimental assay design.

**FIGURE S2** | Evaluation of antidepressant activity using the Forced Swim Test (FST) in healthy and diabetic rats treated with two different zinc compounds (15 mg/kg). C, control group (n = 8); SZ, healthy group supplemented with Zn Sulfate (n = 8); GZ, healthy group supplemented with Zn Gluconate (n = 8); D, diabetic group (n = 10); DSZ, diabetic group supplemented with Zn Sulfate and DGZ (n = 10); Diabetic Group Supplemented with Zn Gluconate (n = 10). Mann–Whitney test (p < 0.05). *Significant difference compared with D group; **significant difference compared with C group.

**FIGURE S3** | Evaluation of motor activity using the Open Field (OF) Test in healthy and diabetic rats treated with two different zinc compounds (15 mg/kg). C, control group (n = 8); SZ, healthy group supplemented with Zn Sulfate (n = 8); GZ, healthy group supplemented with Zn Gluconate (n = 8); D, diabetic group (n = 10); DSZ, diabetic group supplemented with Zn Sulfate and DGZ (n = 10); Diabetic Group Supplemented with Zn Gluconate (n = 10). Mann–Whitney test (p < 0.05). *Significant difference compared with D group; **significant difference compared with C group.

**TABLE S1** | Rearing, grooming and number of fecal cakes quantified in Open Field (OF) Test in healthy and diabetic rats treated with two different zinc compounds (15 mg/kg).

Amara, S., Slama, I. B., Omri, K., Ghoul, E. L., Rhouma, K. B., Abdelmelek, H., et al. (2013). Effects of nanoparticle zinc oxide on emotional behavior and trace elements homeostasis in rat brain. *Toxicol. Ind. Health* 31, 1202–1209. doi: 10.1177/0748233713491802

American Diabetes Association (2017). Standards of medical care in diabetes. *Diabetes Care* 40, S1–S135. doi: 10.2337/dc19-sint01
Ates, M., Dayi, A., Kiray, M., Sisman, A. R., Aglikaya, S., Aksu, I., et al. (2014). Anxiety- and depression-like behavior are correlated with leptin and leptin receptor expression in prefrontal cortex of streptozotocin-induced diabetic rats. Biotech. Histochem. 89, 161–171. doi: 10.3109/10520295.2013.825319

Balhara, Y. S. (2011). Diabetes and psychiatric disorders. Indian J. Endocrinol. Metab. 15, 274–283. doi: 10.4103/2230-8210.85579

Brocardo, P. S., Assini, F., Franco, J. L., Pandolfo, P., Muller, Y. M., Takahashi, R. N., et al. (2007). Zinc attenuates malathion-induced depressant-like behavior and confers neuroprotection in the rat brain. Toxicol. Sci. 97, 140–148. doi: 10.1093/toxsci/kfm024

Candland, D. K., and Campbell, B. A. (1962). Development of fear in the rat as measured by behavior in the open field. J. Comp. Physiol. Psychol. 55, 593–596. doi: 10.1037/h0047206

Captor, J., Foster, M., Petocz, P., and Samman, S. (2013). Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans. J. Trace Elem. Med. Biol. 27, 137–142. doi: 10.1016/j.jtemb.2012.08.001

De Moraes, H., Souza, C. P., Silva, L. M., Ferreira, M. D., Werner, M. F., Andreatini, R., et al. (2014). Increased oxidative stress in prefrontal cortex and hippocampus is related to depressive-like behavior in streptozotocin diabetic rats. Behav. Brain Res. 1, 52–64. doi: 10.1016/j.bbr.2013.10.011

Fernando, J., and Zhou, S. (2015). The role of zinc in renal pathological changes in diabetic status. J. Nutr. Disord. Ther. 5, 1–8. doi: 10.4172/2171-2509.1000165

Gibson, R. S. (2012). Zinc deficiency and human health: etiology, health consequences, and future solutions. Plant Soil 361:291. doi: 10.1007/s11104-012-1204-9

Golden, S. H., Lazo, M., Carnethon, M., Bertoni, A. G., Screiner, P. J., Diez Roux, A. V., et al. (2008). Examining a bidirectional association between depressive symptoms and diabetes. JAMA 299, 2751–2759. doi: 10.1001/jama.299.23.2751

Gronli, J., Soule, J., and Bramham, C. R. (2013). Sleep and protein synthesis-dependent synaptic plasticity: impacts of sleep loss and stress. Front. Behav. Neurosci. 7:224. doi: 10.3389/fnbeh.2013.00224

Gronli, O., Kvanme, J. M., Friborg, O., and Wynn, R. (2013). Zinc deficiency is common in several psychiatric disorders. PLoS One 8:e82793. doi: 10.1371/journal.pone.008287

Hagmeyer, S., Haderspeck, J. C., and Grabrucker, A. M. (2015). Behavioral impairments in animal models for zinc deficiency. Front. Behav. Neurosci. 8:443. doi: 10.3389/fnbeh.2014.00443

Huang, M., Gao, L., Yang, L., Lin, F., and Lei, H. (2012). Abnormalities in the leptin receptor expression in prefrontal cortex of streptozotocin-induced diabetic rats. J. Vet. Sci. 15, 274–283. doi: 10.4103/2230-8587(2012)00045-5

K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Biochim. Biophys. Acta 27, 137–142. doi: 10.1016/j.jtemb.2012.08.001

Kuma, M., et al. (2012). Time course of zinc deprivation-induced alterations in animal models of anxiety, depression and psychosis. Neuropsychiatr. Dis. Treat 7, 3ñ7. doi: 10.2147/NDT.S19617

M, et al. (2012). Zinc status is related to depressive-like behavior in streptozotocin diabetic rats. J. Affect. Disord. 249ñ255. doi: 10.1016/S1734-1140(12)70852-6

Opoka, W., et al. (2010). Serum zinc level in depressed patients during zinc supplementation. J. Cereb. Blood Flow Metab. 30, 1422–1427. doi: 10.1038/jcbfm.2010.116

Sapota, A., Daragó, A., Skrzypińska-Gawrysiak, M., Nasiadek, M., Klimczak, M., Olechnowicz, J., et al. (2014). Increased oxidative stress in prefrontal cortex and hippocampus is related to depressive-like behavior in streptozotocin diabetic rats. J. Vet. Sci. 15, 274–283. doi: 10.4103/2230-8587(2012)00045-5

Plum, L. M., Rink, L., and Haase, H. (2010). The essential toxin: impact of zinc on human health. Int. J. Environ. Res. Public Health 7, 1342–1365. doi: 10.3390/ijerph7041342

Porsolt, R. D. (1979). Animal model of depression. Biomed. Pharmacother. 33, 139–140.

Prabhakar, V., Gupta, D., Kanade, P., and Radhakrishnan, M. (2015). Diabetes-associated depression: the serotoninergic system as a novel multifunctional target. Indian J. Pharmacol. 47, 4–12. doi: 10.4103/0253-7613.150305

Ranasinghe, P., Piqera, S., Galappathy, P., Katulanda, P., and Constantine, G. R. (2015). Zinc and diabetes mellitus: understanding molecular mechanisms and clinical implications. Daru 23, 1–23. doi: 10.1186/s40199-015-0127-4

Ranjbar, E., Kaseai, M. S., Mohammad-Shirazi, M., Nasrollahzadeh, J., Rashidkhani, B., Shams, J., et al. (2013). Effects of zinc supplementation in patients with major depression: a randomized clinical trial. Iran J. Psychiatry 8, 73–79.

Roozani, N., Hurrell, R., Kelishadi, R., and Schulin, R. (2013). Zinc and its importance for human health: an integrative review. J. Res. Med. Sci. 18, 144–157.

Rotella, F., and Mannucci, E. (2013). Depression as a risk factor for diabetes: a metaanalysis of longitudinal studies. J. Clin. Psychiatry 74, 31–37. doi: 10.4088/JCP.1207922

Santos, R. X., Correia, S. C., Alves, M. G., Oliveira, P. F., Cardoso, S., Carvalho, C., et al. (2014). Insulin therapy modulates mitochondrial dynamics and biogenesis, autophagy and tau protein phosphorylation in the brain of type 1 diabetic rats. Biochim. Biophys. Acta 1842, 1154–1166. doi: 10.1016/j.bbadis.2014.04.011

Sapota, A., Daragó, A., Skrzypińska-Gawrysiak, M., Nasiadek, M., Klimczak, M., and Kilanowicz, A. (2014). The bioavailability of different zinc compounds used as human dietary supplements in rat prostate: a comparative study. Biometal 27, 495–505. doi: 10.5936/jbm.140034

Sarti, S. B., Hauschild, M., Bunck, M., Gaburro, S., Landgraf, R., and Singewald, N. (2011). Enhanced fear expression in a psychopathological mouse model of trait anxiety: pharmacological interventions. PLoS One 6:e16849. doi: 10.1371/journal.pone.0016849

Satala, G., Duszyńska, B., Stachowicz, K., Rafalo, A., Pochwaut, B., Luckhart, C., et al. (2016). Concentration-dependent dual mode of Zn action at serotonin 5-HT1A receptors in vitro and in vivo studies. Mol. Neurobiol. 53, 6869–6881. doi: 10.1007/s12035-015-9586-3

Sensi, S. L., and Jeng, J. M. (2004). Rethinking the excitotoxic ionic milieu, the emerging role of Zn2+ in ischemic neuronal injury. Curr. Mol. Med. 4, 151–160. doi: 10.2174/1566524043479211

Slattery, D. A., and Cryan, J. F. (2012). Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat. Protoc. 7, 1009–1014. doi: 10.1038/nprot.2012.044
Strandberg, R. B., Graue, M., Wentzel-Larsen, T., Peyrot, M., and Rokne, B. (2014). Relationships of diabetes-specific emotional distress, depression, anxiety, and overall well-being with HbA1c in adult persons with type 1 diabetes. *J. Psychosom. Res.* 77, 174–179. doi: 10.1016/j.jpsychres.2014.06.015

Suzuki, M., Sasabe, J., Furuya, S., Mita, M., Hamase, K., and Aiso, S. (2012). Type 1 diabetes mellitus in mice increases hippocampal d-serine in the acute phase after streptozotocin injection. *Brain Res.* 1466, 167–176. doi: 10.1016/j.brainres.2012.05.042

Szewczyk, B. (2013). Zinc homeostasis and neurodegenerative disorders. *Front. Aging Neurosci.* 5:33. doi: 10.3389/fnagi.2013.00033

Szewczyk, B., Graue, M., Wentzel-Larsen, T., Peyrot, M., and Rokne, B. (2008). Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. *Pharmacol. Rep.* 60, 588–599.

Szewczyk, B., Kubera, M., and Nowak, G. (2011). The role of zinc neurodegenerative inflammatory pathways in depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 35, 693–701. doi: 10.1016/j.pnpbp.2010.02.010

Takeda, A., Tamano, H., Kan, F., Itoh, H., and Oku, N. (2007). Anxiety-like behavior of young rats after 2-week zinc deprivation. *Behav. Brain Res.* 177, 1–6. doi: 10.1016/j.bbr.2006.11.02

Takeda, A., Tamano, H., Ogawa, T., Takada, S., Ando, M., Oku, N., et al. (2012). Significance of serum glucocorticoid and chelatable zinc in depression and cognition in zinc deficiency. *Behav. Brain Res.* 226, 259–264. doi: 10.1016/j.bbr.2011.09.026

Tassabehji, N. M., Corniola, R. S., Alshingiti, A., and Levenson, C. W. (2008). Zinc deficiency induces depression-like symptoms in adult rats. *Physiol. Behav.* 95, 365–369. doi: 10.1016/j.physbeh.2008.06.017

Torabi, M., Kesmati, M., Harooni, H. E., and Varzi, H. N. (2013). Effects of nano and conventional Zinc Oxide on anxiety-like behavior in male rats. *Indian J. Pharmacol.* 45, 508–512. doi: 10.4103/0253-7613.117784

Wayhs, C. A., Mescka, C. P., Vanzin, C. S., Ribas, G. S., Guerreiro, G., Nin, M. S., et al. (2013). Brain effect of insulin and clonazepam in diabetic rats under depressive-like behavior. *Metab. Brain Dis.* 28, 563–570. doi: 10.1007/s11011-013-9397-z

Wayhs, C. A. Y., Manfredini, V., Sitta, A., Deon, M., Ribas, G., Vanzin, C., et al. (2010). Protein and lipid oxidative damage in streptozotocin-induced diabetic rats submitted to forced swimming test: the insulin and clonazepam effect. *Metab. Brain Dis.* 25, 297–304. doi: 10.1007/s11011-010-9211-0

Whittle, N., Lubec, G., and Singewald, N. (2008). Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice. *Amino. Acids* 36, 147–158. doi: 10.1007/s00726-008-0195-6

Xie, Y., Wang, Y., Zhang, T., Ren, G., and Yang, Z. (2012). Effects of nanoparticle zinc oxide on spatial cognition and synaptic plasticity in mice with depressive-like behaviors. *J. Biomed. Sci.* 19, 1–11. doi: 10.1186/1423-0127-19-14

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Cavalcanti, Gonçalves, Alves, Araújo, Carvalho, Lins, Alves, Soares, Pordeus and Aquino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.